ProVise Management Group’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.1M | Buy |
26,181
+1
| +0% | +$371 | 0.68% | 45 |
|
|
2026
Q1 | $7.66M | Buy |
26,180
+1,176
| +5% | +$387K | 0.55% | 50 |
|
|
2025
Q4 | $8.77M | Buy |
25,004
+1,938
| +8% | +$655K | 0.62% | 48 |
|
|
2025
Q3 | $7.45M | Sell |
23,066
-458
| -2% | -$142K | 0.55% | 50 |
|
|
2025
Q2 | $9.15M | Buy |
23,524
+3,277
| +16% | +$1.32M | 0.72% | 46 |
|
|
2025
Q1 | $8.81M | Buy |
20,247
+3,104
| +18% | +$1.25M | 0.75% | 46 |
|
|
2024
Q4 | $6.32M | Sell |
17,143
-4,665
| -21% | -$1.95M | 0.54% | 52 |
|
|
2024
Q3 | $11.3M | Buy |
21,808
+606
| +3% | +$324K | 0.9% | 32 |
|
|
2024
Q2 | $11.5M | Buy |
21,202
+433
| +2% | +$229K | 0.98% | 31 |
|
|
2024
Q1 | $10.8M | Buy |
20,769
+1,805
| +10% | +$898K | 0.93% | 34 |
|
|
2023
Q4 | $8.94M | Buy |
18,964
+2,195
| +13% | +$1.01M | 0.76% | 39 |
|
|
2023
Q3 | $7.3M | Buy |
16,769
+12,913
| +335% | +$5.86M | 0.68% | 44 |
|
|
2023
Q2 | $1.71M | Buy |
3,856
+22
| +0.6% | +$10.1K | 0.16% | 136 |
|
|
2023
Q1 | $1.76M | Sell |
3,834
-450
| -11% | -$214K | 0.17% | 124 |
|
|
2022
Q4 | $2.2M | Sell |
4,284
-1,692
| -28% | -$859K | 0.22% | 113 |
|
|
2022
Q3 | $2.71M | Sell |
5,976
-640
| -10% | -$306K | 0.3% | 92 |
|
|
2022
Q2 | $3.19M | Sell |
6,616
-853
| -11% | -$422K | 0.34% | 86 |
|
|
2022
Q1 | $3.67M | Sell |
7,469
-392
| -5% | -$179K | 0.35% | 83 |
|
|
2021
Q4 | $3.64M | Sell |
7,861
-55
| -0.7% | -$23.1K | 0.33% | 84 |
|
|
2021
Q3 | $2.95M | Sell |
7,916
-80
| -1% | -$30.4K | 0.29% | 97 |
|
|
2021
Q2 | $3.05M | Sell |
7,996
-107
| -1% | -$40.9K | 0.31% | 89 |
|
|
2021
Q1 | $2.91M | Buy |
8,103
+1,023
| +14% | +$329K | 0.31% | 96 |
|
|
2020
Q4 | $2.27M | Buy |
7,080
+668
| +10% | +$205K | 0.26% | 100 |
|
|
2020
Q3 | $1.72M | Buy |
6,412
+3,927
| +158% | +$1.06M | 0.23% | 107 |
|
|
2020
Q2 | $654K | Buy |
2,485
+206
| +9% | +$55K | 0.09% | 163 |
|
|
2020
Q1 | $517K | Buy |
2,279
+330
| +17% | +$89.9K | 0.09% | 169 |
|
|
2019
Q4 | $589K | Buy |
1,949
+60
| +3% | +$16.5K | 0.07% | 187 |
|
|
2019
Q3 | $454K | Buy |
1,889
+115
| +6% | +$31.5K | 0.06% | 203 |
|
|
2019
Q2 | $501K | Buy |
+1,774
| New | +$485K | 0.07% | 203 |
|
|
2018
Q3 | – | Sell |
-20
| Closed | -$4.76M | – | 328 |
|
|
2018
Q2 | $4.76M | Buy |
+20
| New | +$4.63K | 0.36% | 68 |
|
Other funds holding ELV
ProVise Management Group's ELV Position: Q2 2026 in Review
ProVise Management Group increased its Elevance Health (ELV) stake by 0% in Q2 2026, buying an estimated $371 and bringing the position to 26,181 shares worth $10.1M. The position accounts for 0.68% of the portfolio, ranked #45.
ProVise Management Group first reported a position in ELV in Q2 2018 and has held it in 30 quarters since. The position peaked at $11.5M in Q2 2024. 1,612 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- ProVise Management Group held 26,181 shares of Elevance Health worth $10.1M as of Q2 2026.
- ProVise Management Group bought 1 Elevance Health share in Q2 2026, an estimated $371.
- Elevance Health made up 0.68% of ProVise Management Group's portfolio in Q2 2026, its #45 holding.
- ProVise Management Group first reported a position in Elevance Health in Q2 2018 and has held it in 30 quarters since.
- ProVise Management Group's Elevance Health position peaked at $11.5M in Q2 2024.
- 1,612 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on ProVise Management Group's 13F filing for Q2 2026, filed 3 Aug 2026.